Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause ...

R oche’s Genentech has reported new five-year data from the Phase III Portal trial, confirming the safety, durability, and ...

Genentech's Portal study shows Susvimo maintains vision and retinal drying in wet AMD patients over five years with biannual ...

Basel, 04 February 2025- Roche announced today that the US Food and Drug Administration has approved Susvimo ® 100 mg/mL for the treatment of diabetic macular edema, a leading cause of vision ...

Two-year Phase III data presented at ASRS 2024 show Susvimo’ s potential as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy Safety data were consistent ...

Susvimo is a vascular endothelial growth factor (VEGF) inhibitor indicated for patients with wet AMD who have previously responded to at least 2 intravitreal injections of a VEGF inhibitor medication.

Susvimo is also indicated for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular edema, in patients who have previously responded to at least 2 intravitreal ...

The FDA approved Susvimo 100 mg/mL to treat diabetic retinopathy, according to a press release from Genentech.The approval was supported by positive 1-year data from the phase 3 Pavilion study in ...

The Susvimo implant and the procedures associated with inserting, filling, refilling, and (if medically necessary) removing the implant can cause other serious side effects, including: ...

The Susvimo implant and the procedures associated with inserting, filling, refilling, and (if medically necessary) removing the implant can cause other serious side effects, including: ...

These long-term results reinforce Susvimo’s ability to maintain vision and retinal drying over a long period of time for people with wet AMD, the leading cause of vision loss in people over age 60,” ...

Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic macular edema (DME) and diabetic retinopathy (DR)Safety data were ...